How Lidocaine Treats Ventricular Arrhythmias
Lidocaine is a class IB antiarrhythmic drug that stabilizes ventricular myocardium by blocking voltage- and pH-dependent sodium channels, particularly in ischemic tissue, thereby increasing the ventricular fibrillation threshold and interrupting re-entrant tachycardias. 1, 2
Mechanism of Action
Lidocaine works by binding primarily to inactivated sodium channels, which produces several key electrophysiologic effects:
- Decreases action potential duration in ventricular tissue
- Increases the refractory period without significantly affecting normal conduction
- Preferentially suppresses abnormal automaticity in ischemic myocardium
- Raises the ventricular fibrillation threshold, making it harder for lethal arrhythmias to develop 2
The drug is particularly effective in ischemic tissue because it binds more readily to sodium channels in acidotic, depolarized cells—exactly the conditions present during myocardial infarction 1, 2. This selectivity explains why lidocaine works well for acute ischemia-related arrhythmias but less effectively for chronic ventricular ectopy 3.
Clinical Indications
Lidocaine is indicated for:
- Ventricular tachycardia (hemodynamically stable)
- Ventricular fibrillation resistant to defibrillation
- Frequent ventricular premature beats (>6/min)
- Closely coupled PVCs (R-on-T phenomenon)
- Multiform ventricular ectopy
- Runs of 3 or more consecutive PVCs 4
Important Context on Efficacy
While lidocaine reduces the incidence of ventricular arrhythmias including VF, trials have failed to demonstrate that it reduces overall mortality in acute MI 4. There is an increased incidence of asystole with lidocaine that may offset its benefits in suppressing ventricular ectopy 4. This is why prophylactic lidocaine is no longer routinely recommended 4, 5.
Dosing Regimen
Initial Loading Dose
- 1 mg/kg IV bolus (maximum 100 mg) given over 2 minutes 4
- Additional 0.5 mg/kg boluses can be given every 8-10 minutes if needed, up to a total of 4 mg/kg 4
Maintenance Infusion
- 20-50 μg/kg/min (1.4-3.5 mg/min in a 70 kg patient, typically 2-4 mg/min) 4, 1
- Target therapeutic plasma level: 1.5-5.0 μg/mL 6
- For heart failure patients: start at 1 mg/min (lower rates needed due to impaired hepatic clearance) 6
Critical Dosing Considerations
A second bolus of 0.5 mg/kg is often necessary 30-120 minutes after starting the infusion because patients experience transient subtherapeutic levels during this window 4. Simply increasing the infusion rate without a bolus takes >6 hours to reach therapeutic levels 4.
After 12-24 hours, reduce the infusion rate by 1 mg/min because lidocaine's half-life increases significantly after 24-48 hours of therapy 4.
Cardiac Arrest Dosing
- 100 mg bolus for ventricular fibrillation
- Can repeat every 2-3 minutes as needed
- It takes approximately 2 minutes for lidocaine to reach central circulation 4
Pharmacokinetics and Dose Adjustments
Lidocaine is almost exclusively eliminated by the liver 4. The half-life varies dramatically based on clinical status:
- Normal subjects: 1-2 hours
- Uncomplicated MI: >4 hours
- MI with heart failure: >20 hours
- Cardiogenic shock: even longer 4
Mandatory dose reductions are required for:
- Patients >70 years old
- Congestive heart failure or cardiogenic shock
- Hepatic dysfunction
- Severe renal dysfunction 4
Dosing should be based on lean body weight to avoid toxicity 4.
Toxicity Recognition and Management
CNS Toxicity (Most Common)
Early warning signs include:
- Perioral numbness
- Dizziness, drowsiness
- Tinnitus
- Confusion, slurred speech
- Muscle twitching
- Seizures (late sign) 4, 7
Cardiovascular Toxicity
- Bradycardia
- Sinus arrest
- Hypotension
- Asystole 4
Management: Immediate discontinuation of lidocaine and benzodiazepines for seizures 7. Resuscitative equipment must be immediately available 8.
Current Role vs. Amiodarone
The 2025 AHA guidelines now favor amiodarone, procainamide, or sotalol over lidocaine for stable wide-complex tachycardia 9. Direct comparisons show that lidocaine's kinetic properties make it less effective than these alternatives for hemodynamically tolerated VT, and it's unclear if lidocaine is even more effective than placebo in this setting 9.
However, lidocaine retains specific utility:
- First-line for VT in acute MI settings where ischemia is the primary mechanism 1
- Combination therapy with amiodarone for refractory ventricular arrhythmias shows promise 10
- EMS transport situations where recurrent VF/VT would be logistically difficult to manage 5
Key Limitation
Lidocaine has NO effect on supraventricular tachycardias 1. Do not use it for narrow-complex tachycardias.
Common Pitfalls
- Forgetting the second bolus at 30-120 minutes leads to treatment failure due to subtherapeutic levels 4
- Not reducing doses in elderly or heart failure patients causes toxicity 4, 6
- Increasing infusion rate without a bolus when arrhythmias recur—this takes >6 hours to work 4
- Continuing the same infusion rate beyond 24 hours without reduction causes accumulation 4
- Using lidocaine prophylactically in all MI patients—this increases asystole risk without mortality benefit 4, 5
Monitor plasma levels when using high infusion rates, prolonged therapy, or if neurologic changes occur 4.